Publication Date:
2013-04-06
Description:
A number of human cancers harbor somatic point mutations in the genes encoding isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2). These mutations alter residues in the enzyme active sites and confer a gain-of-function in cancer cells, resulting in the accumulation and secretion of the oncometabolite (R)-2-hydroxyglutarate (2HG). We developed a small molecule, AGI-6780, that potently and selectively inhibits the tumor-associated mutant IDH2/R140Q. A crystal structure of AGI-6780 complexed with IDH2/R140Q revealed that the inhibitor binds in an allosteric manner at the dimer interface. The results of steady-state enzymology analysis were consistent with allostery and slow-tight binding by AGI-6780. Treatment with AGI-6780 induced differentiation of TF-1 erythroleukemia and primary human acute myelogenous leukemia cells in vitro. These data provide proof-of-concept that inhibitors targeting mutant IDH2/R140Q could have potential applications as a differentiation therapy for cancer.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Wang, Fang -- Travins, Jeremy -- DeLaBarre, Byron -- Penard-Lacronique, Virginie -- Schalm, Stefanie -- Hansen, Erica -- Straley, Kimberly -- Kernytsky, Andrew -- Liu, Wei -- Gliser, Camelia -- Yang, Hua -- Gross, Stefan -- Artin, Erin -- Saada, Veronique -- Mylonas, Elena -- Quivoron, Cyril -- Popovici-Muller, Janeta -- Saunders, Jeffrey O -- Salituro, Francesco G -- Yan, Shunqi -- Murray, Stuart -- Wei, Wentao -- Gao, Yi -- Dang, Lenny -- Dorsch, Marion -- Agresta, Sam -- Schenkein, David P -- Biller, Scott A -- Su, Shinsan M -- de Botton, Stephane -- Yen, Katharine E -- New York, N.Y. -- Science. 2013 May 3;340(6132):622-6. doi: 10.1126/science.1234769. Epub 2013 Apr 4.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Agios Pharmaceuticals, Cambridge, MA 02139-4169, USA.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/23558173" target="_blank"〉PubMed〈/a〉
Keywords:
Allosteric Site
;
Antineoplastic Agents/chemistry/metabolism/pharmacology
;
Catalytic Domain
;
Cell Line, Tumor
;
Cell Proliferation
;
Cells, Cultured
;
Crystallography, X-Ray
;
Enzyme Inhibitors/chemistry/metabolism/*pharmacology
;
Erythropoiesis/drug effects
;
Gene Expression Regulation, Leukemic
;
Glutarates/metabolism
;
Hematopoiesis/*drug effects
;
Humans
;
Isocitrate Dehydrogenase/*antagonists & inhibitors/chemistry/*genetics/metabolism
;
Leukemia, Erythroblastic, Acute
;
Leukemia, Myeloid, Acute/drug therapy/*enzymology/genetics/pathology
;
Molecular Targeted Therapy
;
Mutant Proteins/antagonists & inhibitors/chemistry/metabolism
;
Phenylurea Compounds/chemistry/metabolism/*pharmacology
;
Point Mutation
;
Protein Multimerization
;
Protein Structure, Secondary
;
Small Molecule Libraries
;
Sulfonamides/chemistry/metabolism/*pharmacology
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics
